Skip to main content

Advertisement

SpringerLink
Log in

The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin Signaling and Implications for Clinical Trials

  • Review
  • Published:
The Journal of Frailty & Aging Aims and scope Submit manuscript

Abstract

The age-related loss of skeletal muscle (sarcopenia) is a major health concern as it is associated with physical disability, metabolic impairments, and increased mortality. The coexistence of sarcopenia with obesity, termed ‘sarcopenic obesity’, contributes to skeletal muscle insulin resistance and the development of type 2 diabetes, a disease prevalent with advancing age. Despite this knowledge, the mechanisms contributing to sarcopenic obesity remain poorly understood, preventing the development of targeted therapeutics. This article will discuss the clinical and physiological consequences of sarcopenic obesity and propose myostatin as a potential candidate contributing to this condition. A special emphasis will be placed on examining the role of myostatin signaling in impairing both skeletal muscle growth and insulin signaling. In addition, the role of myostatin in regulating muscle-to fat cross talk, further exacerbating metabolic dysfunction in the elderly, will be highlighted. Lastly, we discuss how this knowledge has implications for the design of myostatin-inhibitor clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care 2008;11:693–700.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Cauley JA. An Overview of Sarcopenic Obesity. Curr Opin Clin Nutr Metab Care 2015;18:499–505.

    Google Scholar 

  3. Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Curr Opin Clin Nutr Metab Care 2004;12:887–888.

    Google Scholar 

  4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.

    PubMed  CAS  Google Scholar 

  5. Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol 2016;229:R67–81.

    Article  PubMed  CAS  Google Scholar 

  6. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83–90.

    Article  PubMed  CAS  Google Scholar 

  7. Garber K. No longer going to waste. Nat Biotechnol 2016;34:458–461.

    Article  PubMed  CAS  Google Scholar 

  8. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016 Jan 3-. Identifier NCT03021798, An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over (SARAOBS). Available from: https://clinicaltrials.gov/ct2/show/NCT03021798?term=NCT03021798&rank=1

  9. Kocsis T, Trencsenyi G, Szabo K, et al. Myostatin propeptide mutation of the hypermuscular Compact mice decreases the formation of myostatin and improves insulin sensitivity. Am J Physiol Endocrinol Metab 2017;312:e150-E160.

    Article  Google Scholar 

  10. Sharma M, Kambadur R, Matthews KG, et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999;180:1–9.

    Article  PubMed  CAS  Google Scholar 

  11. Goodman CA, McNally RM, Hoffmann FM, Hornberger TA. Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo. Mol Endocrinol 2013;27:1946–1957.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 2009;297:C1124–1132.

    Article  PubMed  CAS  Google Scholar 

  13. Yarasheski KE, Bhasin S, Sinha-Hikim I, Pak-Loduca J, Gonzalez-Cadavid NF. Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J Nutr Health Aging 2002;6:343–348.

    PubMed  CAS  Google Scholar 

  14. Leger B, Derave W, De Bock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 2008;11:163–175B.

    Article  PubMed  CAS  Google Scholar 

  15. Han DS, Chen YM, Lin SY, et al. Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis. Clin Endocrinol (Oxf) 2011;75:857–863.

    Article  CAS  Google Scholar 

  16. Patel HP, Al-Shanti N, Davies LC, et al. Lean mass, muscle strength and gene expression in community dwelling older men: findings from the Hertfordshire Sarcopenia Study (HSS). Calcif Tissue Int 2014;95:308–316.

    Article  PubMed  CAS  Google Scholar 

  17. Tay L, Ding YY, Leung BP, et al. Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults. Age (Dordr) 2015;37:121.

    Article  CAS  Google Scholar 

  18. Hofmann M, Halper B, Oesen S, et al. Serum concentrations of insulinlike growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women. Exp Gerontol 2015;64:35–45.

    Article  PubMed  Google Scholar 

  19. Ratkevicius A, Joyson A, Selmer I, et al. Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J Gerontol A Biol Sci Med Sci 2011;66:620–626.

    Article  PubMed  CAS  Google Scholar 

  20. Bergen HR, 3rd, Farr JN, Vanderboom PM, et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle 2015;5:21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Borkan GA, Hults DE, Gerzof SG, Robbins AH, Silbert CK. Age changes in body composition revealed by computed tomography. J Gerontol 1983;38:673–677.

    Article  PubMed  CAS  Google Scholar 

  22. Consitt LA, Van Meter J, Newton CA, et al. Impairments in site-specific AS160 phosphorylation and effects of exercise training. Diabetes 2013;62:3437–3447.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009;58:30–38.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Hjorth M, Pourteymour S, Gorgens SW, et al. Myostatin in relation to physical activity and dysglycaemia and its effect on energy metabolism in human skeletal muscle cells. Acta Physiol (Oxf) 2016;217:45–60.

    Article  CAS  Google Scholar 

  25. Ryan AS, Li G, Blumenthal JB, Ortmeyer HK. Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity (Silver Spring) 2013;21:1350–1356.

    Article  CAS  Google Scholar 

  26. Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One 2009;4:e4937.

    Article  CAS  Google Scholar 

  27. DeFronzo RA. Glucose intolerance and aging. Diabetes Care 1981;4:493–501.

    Article  PubMed  CAS  Google Scholar 

  28. Palsgaard J, Brons C, Friedrichsen M, et al. Gene expression in skeletal muscle biopsies from people with type 2 diabetes and relatives: differential regulation of insulin signaling pathways. PLoS One 2009;4:e6575.

    Article  CAS  Google Scholar 

  29. Milan G, Dalla Nora E, Pilon C, et al. Changes in muscle myostatin expression in obese subjects after weight loss. J Clin Endocrinol Metab 2004;89:2724–2727.

    Article  PubMed  CAS  Google Scholar 

  30. Camporez JP, Petersen MC, Abudukadier A, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice. Proc Natl Acad Sci U S A 2016;113:2212–2217.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 2009;297:C1124–1132.

    Article  PubMed  CAS  Google Scholar 

  32. Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM, Kraus WE. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc 2010;42:2023–2029.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Zhang C, McFarlane C, Lokireddy S, et al. Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia 2011;54:1491–1501.

    Article  PubMed  CAS  Google Scholar 

  34. Tang L, Liu CT, Wang XD, et al. A prepared anti-MSTN polyclonal antibody reverses insulin resistance of diet-induced obese rats via regulation of PI3K/Akt/mTOR&FoxO1 signal pathways. Biotechnol Lett 2014;36:2417–2423.

    Article  PubMed  CAS  Google Scholar 

  35. Shan T, Liang X, Bi P, Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1alpha-Fndc5 pathway in muscle. FASEB J 2013;27:1981–1989.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Dong J, Dong Y, Dong Y, Chen F, Mitch WE, Zhang L. Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. Int J Obes (Lond) 2016;40:434–442.

    Article  CAS  Google Scholar 

  37. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003;300:1140–1142.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Consitt LA, Bell JA, Koves TR, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha overexpression increases lipid oxidation in myocytes from extremely obese individuals. Diabetes 2010;59:1407–1415.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Michael LF, Wu Z, Cheatham RB, et al. Restoration of insulinsensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci U S A 2001;98:3820–3825.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Pauly M, Chabi B, Favier FB, et al. Combined Strategies for Maintaining Skeletal Muscle Mass and Function in Aging: Myostatin Inactivation and AICAR-Associated Oxidative Metabolism Induction. J Gerontol A Biol Sci Med Sci 2015;70:1077–1087.

    Article  PubMed  CAS  Google Scholar 

  41. Takahashi H, Sato K, Yamaguchi T, et al. Myostatin alters glucose transporter-4 (GLUT4) expression in bovine skeletal muscles and myoblasts isolated from double-muscled (DM) and normal-muscled (NM) Japanese shorthorn cattle. Domest Anim Endocrinol 2014;48:62–68.

    Article  PubMed  CAS  Google Scholar 

  42. Rodriguez A, Becerril S, Ezquerro S, Mendez-Gimenez L, Fruhbeck G. Crosstalk between adipokines and myokines in fat browning. Acta Physiol (Oxf) 2017;219:362–381.

    Article  CAS  Google Scholar 

  43. Cinti S. The adipose organ at a glance. Dis Model Mech 2012;5:588–594.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Petrovic N, Walden TB, Shabalina IG, Timmons JA, Cannon B, Nedergaard J. Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J Biol Chem 2010;285:7153–7164.

    Article  PubMed  CAS  Google Scholar 

  45. Yoneshiro T, Aita S, Matsushita M, et al. Age-related decrease in coldactivated brown adipose tissue and accumulation of body fat in healthy humans. Obesity (Silver Spring) 2011;19:1755–1760.

    Article  Google Scholar 

  46. Saito M, Okamatsu-Ogura Y, Matsushita M, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 2009;58:1526–1531.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Yang X, Enerback S, Smith U. Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance. Obes Res 2003;11:1182–1191.

    Article  PubMed  CAS  Google Scholar 

  48. Chondronikola M, Volpi E, Borsheim E, et al. Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans. Diabetes 2014;63:4089–4099.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Zhang C, McFarlane C, Lokireddy S, et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia 2012;55:183–193.

    Article  PubMed  CAS  Google Scholar 

  50. Choi SJ, Yablonka-Reuveni Z, et al. Increased energy expenditure and leptin sensitivity account for low fat mass in myostatin-deficient mice. Am J Physiol Endocrinol Metab 2011;300:e1031–1037.

    Article  CAS  Google Scholar 

  51. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013;98:e769–778.

    Article  CAS  Google Scholar 

  52. Chang JS, Kim TH, Nguyen TT, Park KS, Kim N, Kong ID. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. Geriatr Gerontol Int 2017.

    Google Scholar 

  53. Kalinkovich A, Livshits G. Sarcopenia—The search for emerging biomarkers. Ageing Res Rev 2015;22:58–71.

    Article  PubMed  CAS  Google Scholar 

  54. Huh JY, Dincer F, Mesfum E, Mantzoros CS. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. Int J Obes (Lond) 2014;38:1538–1544.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ohio Musculoskeletal and Neurological Institute (OMNI), Athens, Ohio, USA

    Leslie A. Consitt & B. C. Clark

  2. Diabetes Institute, Athens, Ohio, USA

    Leslie A. Consitt

  3. Department of Biomedical Sciences, Athens, Ohio, USA

    Leslie A. Consitt & B. C. Clark

  4. Division of Geriatric Medicine at Ohio University, Athens, Ohio, USA

    B. C. Clark

Authors
  1. Leslie A. Consitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. C. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leslie A. Consitt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Consitt, L.A., Clark, B.C. The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin Signaling and Implications for Clinical Trials. J Frailty Aging 7, 21–27 (2018). https://doi.org/10.14283/jfa.2017.33

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.14283/jfa.2017.33

Key words

Search

Navigation